StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.74−0.15 (-0.79%)

Close on Nov 13, 2026Market cap $3.00BP/E –Yield –

Earnings

Denali Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$17.80M
EPS, Q3 FY2026
$0.37
Latest guidance
Issued
Nov 3, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Denali Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026after the close$17.80M–$0.37Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026during market hours$3.60M–-$0.68Release
Q1 FY2026ended Mar 31, 2026May 7, 2026during market hours––-$0.69Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026during market hours––-$0.73Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours–––Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025during market hours–––Release
Q1 FY2025ended Mar 31, 2025May 6, 2025during market hours––-$0.78Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024during market hours––-$0.63Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024before the open––-$0.59Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours––-$0.68Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Denali Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
net product revenueQ4 FY2026$30.00M – $32.00M–NewNov 3, 2026

Guidance vs results

The last range Denali Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026Revenue$10.00M – $12.00M$17.80MAbove range

Guidance history

Every forecast Denali Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 3, 2026net product revenueQ4 FY2026$30.00M – $32.00MNew
Aug 6, 2026AVLAYAH net product revenueQ3 FY2026$10.00M – $12.00MNew
Feb 27, 2025cash operating expensesFY2025+10% – +15%New
Nov 6, 2024cash operating expensesFY2024+5% – +10%New
Nov 7, 2023cash operating expensesFY2023+15% – +20%Lowered
Feb 27, 2023cash operating expensesFY2023+25% – +30%New
Feb 28, 2022cash operating expensesFY2022+25% – +30%New
Feb 28, 2022incoming cash and milestonesFY2022$100.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Denali Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
    Results
  2. Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
    Results
  3. Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease
    Update
  4. Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
    Update
  5. Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
    Results
  6. Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
    Update
  7. Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
    Results
  8. Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
    Update
  9. Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
    News
  10. 8-K exhibit EX-99.1
    Update
  11. Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
    Results
  12. Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
    Update
  13. Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
    Results
  14. Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
    Update
  15. Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
    Results

See a number that looks wrong?